TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20167994

Group type: EXPERIMENTAL
Intervention: Triomune 40 (GT) - quartered tablet dosing (8-<12 kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Generic liquid (GL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Trade liquid (TL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triomune 40 (GT) - one-half and three-quarter tablet dosing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Comparison with Western paediatric cohorts
Number of subjects: 18
Study: 17379046

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) tramadol 200 mg every morning plus placebo immediate-release (IR) tramadol 50 mg every 4 to 6 hours PRN rescue
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) tramadol 400 mg every morning plus placebo immediate-release (IR) tramadol 100 mg every 4 to 6 hours PRN rescue
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) tramadol
Number of subjects: 122

Group type: COMPARATOR
Intervention: Immediate-release (IR) tramadol
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Biweekly VAS pain intensity questionnaire
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Pain and Disability Index (PDI)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Pain and Sleep Questionnaire
Number of subjects: 122
Study: 16282562

Group type: EXPERIMENTAL
Intervention: Exercise training (walking and weight lifting 3 days/week for 18 months)
Number of subjects: 214
Study: 12081830

Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein isolate (SPI+; n = 24)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Isoflavone-poor soy protein isolate (SPI-; n = 24)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Whey protein (control; n = 21)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: All groups (SPI+ and SPI- compared to control)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 69
Study: 9858441

Group type: EXPERIMENTAL
Intervention: Exercise therapy from a physiotherapist in primary care
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (standard treatment from general practitioner)
Number of subjects: 201
Study: 7832131

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (0.39 +/- 0.19 nmol/kg/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Maximal epinephrine dose in control group
Number of subjects: 8
Study: 2226729

Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside (HD Ara-C) with mitoxantrone (MTX)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside (HD Ara-C) with m-amsacrine (AMSA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: m-amsacrine (AMSA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: mitoxantrone (MTX)
Number of subjects: 52
Study: 349428

Group type: EXPERIMENTAL
Intervention: Pimozide (Orap)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31432332

Group type: EXPERIMENTAL
Intervention: Gluteal turnover flap (GT-flap) for perineal wound closure after APR
Number of subjects: 10
Study: 27742102

Group type: EXPERIMENTAL
Intervention: MyFitnessPal app
Number of subjects: 30

Group type: COMPARATOR
Intervention: Paper tallying of estimated sodium intake
Number of subjects: 30
Study: 26504068

Group type: EXPERIMENTAL
Intervention: Mindfulness workshops (dietetic and psychological approaches)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 53
Study: 23644930

Group type: EXPERIMENTAL
Intervention: 0.5 mg/month IV ibandronate
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: 1 mg/month IV ibandronate
Number of subjects: 1265

Group type: COMPARATOR
Intervention: 2.5 mg/day oral risedronate
Number of subjects: 1265
Study: 21269298

Group type: EXPERIMENTAL
Intervention: Frovatriptan (5.0 mg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 19705288

Group type: EXPERIMENTAL
Intervention: HPV 16 and 18 vaccination
Number of subjects: 1233
Study: 16941972

Group type: EXPERIMENTAL
Intervention: Acupuncture at Dazhui (GV 14)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Intramuscular injection of Antongding Injectio
Number of subjects: 86
Study: 15597291

Group type: EXPERIMENTAL
Intervention: Symptoms reported by LTR with rejection (grade >or= A2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptoms reported by LTR with clinically significant acute rejection (grade >or= A2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptoms (respiratory, general, or activities of daily living [ADL])
Number of subjects: 0
Study: 10786064

Group type: EXPERIMENTAL
Intervention: St. John's Wort (Hypericum perforatum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9183333

Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Combination therapy (low fixed dose warfarin plus aspirin)
Number of subjects: 846

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 846
Study: 8222099

Group type: EXPERIMENTAL
Intervention: CGP 39 393
Number of subjects: 113

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 113
Study: 3759224

Group type: EXPERIMENTAL
Intervention: Diltiazem (180‐270 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nifedipine (40‐60 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 40
Study: 29020866

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study: 26598037

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 65
Study: 25165158

Group type: EXPERIMENTAL
Intervention: Bibliographical support (literature research)
Number of subjects: 201
Study: 23845696

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 20710089

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19123765

Group type: EXPERIMENTAL
Intervention: Deliberate self-harm (DSH) group
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study: 15644657

Group type: EXPERIMENTAL
Intervention: Closed-tracheal suction system
Number of subjects: 443

Group type: COMPARATOR
Intervention: Open tracheal suction system
Number of subjects: 443
Study: 12169860

Group type: EXPERIMENTAL
Intervention: Juice supplemented with Lactobacillus rhamnosus and Propionibacterium freudenreichii
Number of subjects: 28

Group type: COMPARATOR
Intervention: Juice (control group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Juice supplemented with Lactobacillus reuteri
Number of subjects: 28
Study: 12179668

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (2% lidocaine)
Number of subjects: 68
Study: 7781368

Group type: EXPERIMENTAL
Intervention: 10 mg of metoclopramide administered 10 min before tube insertion
Number of subjects: 105

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 105
Study: 2107239

Group type: EXPERIMENTAL
Intervention: Prehospital treatment with recombinant tissue‐type plasminogen activator (rt‐PA) in the mobile intensive care unit (group A)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Hospital treatment (group B)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Prehospital treatment with rt‐PA (group A)
Number of subjects: 118
Study: 7360486

Group type: EXPERIMENTAL
Intervention: Synchronized schedule of VP-16 and adriamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard schedule of VP-16 and adriamycin
Number of subjects: 0
Study: 31941538

Group type: EXPERIMENTAL
Intervention: Care by a PDNS (who works according to a recent guideline on PDNS care)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (without PDNS)
Number of subjects: 240
Study: 30719706

Group type: EXPERIMENTAL
Intervention: Arm A (gender-neutral HPV16/18 vaccination)
Number of subjects: 61935

Group type: COMPARATOR
Intervention: Arm C (gender-neutral HBV vaccination)
Number of subjects: 61935

Group type: EXPERIMENTAL
Intervention: Arm B (girls-only HPV16/18 vaccination and HBV vaccination of boys)
Number of subjects: 61935

Group type: COMPARATOR
Intervention: Non-vaccinated group
Number of subjects: 61935
Study: 30923964

Group type: EXPERIMENTAL
Intervention: Customized cutting block (CCB)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional cutting instrument (CCI)
Number of subjects: 86
Study: 28462794

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) applied to wrist and finger extensors
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no FES)
Number of subjects: 30
Study: 25609935

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Physiotherapy (Control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: All groups (ST, AT, Physiotherapy)
Number of subjects: 22
Study: 23291425

Group type: EXPERIMENTAL
Intervention: NeuroFlo therapy
Number of subjects: 515

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 515
Study: 21571448

Group type: EXPERIMENTAL
Intervention: Abrupt cessation (n=472)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Gradual cessation (n=502)
Number of subjects: 472

Group type: COMPARATOR
Intervention: No preference, randomized to abrupt (n=2456)
Number of subjects: 472

Group type: COMPARATOR
Intervention: No preference, randomized to gradual (n=2456)
Number of subjects: 472
Study: 18053689

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 164
Study: 16830143

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg intravenously every 3 months for 12 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (10 thalassemic osteoporotic patients with serial BMDs)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Zoledronic acid treatment
Number of subjects: 18
Study: 12957974

Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control (none)
Number of subjects: 103
Study: 11056759

Group type: COMPARATOR
Intervention: Systemic Mediator Associated Response Test (SMART) baseline models
Number of subjects: 303

Group type: COMPARATOR
Intervention: Systemic Mediator Associated Response Test (SMART) baseline plus serial data models
Number of subjects: 303

Group type: COMPARATOR
Intervention: SMART predictions of physiologic, respiratory, metabolic, hepatic, renal, and hematologic function indicators
Number of subjects: 303

Group type: COMPARATOR
Intervention: SMART multivariate models
Number of subjects: 303

Group type: COMPARATOR
Intervention: SMART predictions for 28-day survival
Number of subjects: 303
Study: 9058681

Group type: EXPERIMENTAL
Intervention: Flunisolide 500 microg qd in the morning
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Flunisolide 1000 microg qd in the morning
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Flunisolide 1000 microg qd in the evening
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Flunisolide 500 microg bid
Number of subjects: 366
Study: 8138867

Group type: EXPERIMENTAL
Intervention: Treatment instituted at bedtime
Number of subjects: 6
Study: 3763918

Group type: EXPERIMENTAL
Intervention: Ioxaglate sodium meglumine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 0
Study: 29127813

Group type: EXPERIMENTAL
Intervention: Culturally Sensitive Collaborative Treatment (CSCT)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 280
Study: 26802916

Group type: EXPERIMENTAL
Intervention: Medication therapy management (MTM) intervention targeting FRIDs
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no MTM intervention)
Number of subjects: 80
Study: 25366678

Group type: EXPERIMENTAL
Intervention: Bladder-preserving combined-modality therapy (CMT)
Number of subjects: 468
Study: 21858593

Group type: EXPERIMENTAL
Intervention: Suction drains (DN group, n=15)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Quilting sutures (QS group, n=13)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fibrin sealant (FS group, n=15)
Number of subjects: 43
Study: 20349201

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pharmacological treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recent guidelines from various societies
Number of subjects: 0
Study: 19167586

Group type: EXPERIMENTAL
Intervention: Tizanidine 6-mg capsule administered intact
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tizanidine capsule contents sprinkled in applesauce
Number of subjects: 28
Study: 15924530

Group type: EXPERIMENTAL
Intervention: Moxibustion (stimulation with heat from a stick of Artemisia vulgaris) at the BL 67 acupuncture point for one or two weeks
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 123
Study: 13129466

Group type: EXPERIMENTAL
Intervention: High-MUFA diet (33 g dietary SFA/100 g total fatty acids substituted with MUFA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Moderate-MUFA diet (16 g dietary SFA/100 g total fatty acids substituted with MUFA)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: High-MUFA diet
Number of subjects: 51

Group type: COMPARATOR
Intervention: Moderate-MUFA diet
Number of subjects: 51
Study: 10533795

Group type: EXPERIMENTAL
Intervention: UDCA (600 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 45
Study: 8693441

Group type: EXPERIMENTAL
Intervention: Threshold loading device
Number of subjects: 18
Study: 2592983

Group type: COMPARATOR
Intervention: Lateral tilting of the body axis (0 degrees control position to 4, 8, 12, 16, 20 degrees test positions)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lateral tilting of the body axis (various degrees)
Number of subjects: 12
Study: 1246775

Group type: EXPERIMENTAL
Intervention: Resection via perineal urethrostomy (Group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Resection via the entire urethra (Group C)
Number of subjects: 42
Study: 31746962

Group type: EXPERIMENTAL
Intervention: Genetically predicted increase in non-HDL-C levels by 1 SD (38 mg/dL)
Number of subjects: 12460

Group type: EXPERIMENTAL
Intervention: Genetically predicted increase in non-HDL-C levels
Number of subjects: 12460
Study: 30707935

Group type: EXPERIMENTAL
Intervention: Overlay mesh placement (anterior component separation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Underlay mesh placement (posterior component separation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: HADM (human acellular dermis)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PADM (porcine acellular dermis)
Number of subjects: 120
Study: 28651508

Group type: EXPERIMENTAL
Intervention: Earplugs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 25727403

Group type: EXPERIMENTAL
Intervention: Glycine powder air polishing (GPAP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sodium bicarbonate air polishing (SBAP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ultrasonic scaling
Number of subjects: 22
Study: 23715024

Group type: EXPERIMENTAL
Intervention: Double continuous epidural analgesia (CEA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Single continuous epidural analgesia (CEA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA)
Number of subjects: 66
Study: 21617983

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg/day)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg/day) + Tolterodine (2 mg/day)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (Tamsulosin alone)
Number of subjects: 250
Study: 19222922

Group type: EXPERIMENTAL
Intervention: 300 mg tenofovir tablet formulation
Number of subjects: 43
Study: 22276820

Group type: EXPERIMENTAL
Intervention: Epirubicin and cyclophosphamide followed by docetaxel plus bevacizumab
Number of subjects: 1948

Group type: COMPARATOR
Intervention: Epirubicin and cyclophosphamide followed by docetaxel
Number of subjects: 1948
Study: 15796639

Group type: EXPERIMENTAL
Intervention: URICA scale
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Cluster analyses
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Continuous measure of readiness to change
Number of subjects: 234
Study: 12534446

Group type: EXPERIMENTAL
Intervention: Iloprost administered for 5 days in SSc patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iloprost administered for 21 days in PAD patients
Number of subjects: 40
Study: 9842825

Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM) or sufentanil (ES) combined with bupivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intramuscular morphine (IM) at fixed intervals
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil and morphine combined with bupivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous sufentanil (IV)
Number of subjects: 90
Study: 8017740

Group type: EXPERIMENTAL
Intervention: 10 mg enoxaparin once daily
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin once daily
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: 30 mg enoxaparin every 12 hours
Number of subjects: 572
Study: 2679036

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 1278069

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 1593

Group type: EXPERIMENTAL
Intervention: Management strategies suggested include maximisation of efforts to enlist subject cooperation, management by family doctor or health centre, flexible appointment scheduling, and minimisation of doctors' ambivalence about treatment effectiveness.
Number of subjects: 1593

Group type: EXPERIMENTAL
Intervention: Alternatives such as low salt diets are suggested for further research due to the inevitability of some subjects rejecting long-term drug treatment.
Number of subjects: 1593
Study: 31512067

Group type: EXPERIMENTAL
Intervention: Facilitator-led, curriculum-driven small-group behavioral intervention
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control clinics (no intervention)
Number of subjects: 1000
Study: 30149414

Group type: EXPERIMENTAL
Intervention: Specific exercise program over six weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Massage therapy (control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Specific exercise program
Number of subjects: 28
Study: 27471836

Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine artery occlusion in combination with laparoscopic myomectomy (LUAO+LM)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Laparoscopic myomectomy (LM) alone
Number of subjects: 618
Study: 24736093

Group type: EXPERIMENTAL
Intervention: HPV self-sampling device
Number of subjects: 30130

Group type: COMPARATOR
Intervention: Regular cervical screening
Number of subjects: 30130

Group type: EXPERIMENTAL
Intervention: Self-sampling device
Number of subjects: 30130
Study: 22101054

Group type: EXPERIMENTAL
Intervention: Synbiotic yogurt containing B. animalis subsp. lactis Bb‐12 and inulin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Synbiotic yogurt
Number of subjects: 46
Study: 20736784

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Disease Management Program (DMP), n = 86
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual care, n = 87
Number of subjects: 173
Study: 18786762

Group type: EXPERIMENTAL
Intervention: Graded Exposure (GX)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Treatment-Based Classification (TBC)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Graded Activity (GA)
Number of subjects: 108
Study: 15824161

Group type: EXPERIMENTAL
Intervention: 400 mg/wk oral oltipraz
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 200 mg/wk oral oltipraz
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 12451428

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (250 ml) with diltiazem (120 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water with diltiazem (120 mg)
Number of subjects: 10
Study: 10511903

Group type: EXPERIMENTAL
Intervention: Antibiotics for initial treatment of bacterial complications of acute respiratory tract viral infections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unjustified use of antibiotics
Number of subjects: 0
Study: 7713831

Group type: EXPERIMENTAL
Intervention: Melatonin administration (100 mg at 0800)
Number of subjects: 2
Study: 2288898

Group type: EXPERIMENTAL
Intervention: Histamine dry skin prick test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control prick test
Number of subjects: 0
Study: 6106149

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30172595

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5-3 mg/d
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Cariprazine 4.5-6 mg/d
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg/d
Number of subjects: 273

Group type: COMPARATOR
Intervention: Aripiprazole 10 mg/d
Number of subjects: 273
Study: 28402521

Group type: EXPERIMENTAL
Intervention: Piezosurgery-assisted en-masse retraction
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional en-masse retraction (Control)
Number of subjects: 31
Study: 26696199

Group type: EXPERIMENTAL
Intervention: House dust mite subcutaneous immunotherapy (SCIT) for 3 years
Number of subjects: 102

Group type: COMPARATOR
Intervention: Symptomatic therapy (ST)
Number of subjects: 102
Study: 23332481

Group type: EXPERIMENTAL
Intervention: Behavioral health music therapy intervention
Number of subjects: 16